Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03015610 · ClinicalTrials.gov registry record · Phase 3
Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma
A Phase 3 study of Asthma and Gastroesophageal Reflux, sponsored by Jason Lang, M.D., M.P.H..
- Completed
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
- 2
- Study locations
NCT03015610 is a Phase 3 study of Asthma and Gastroesophageal Reflux that has completed, run by Jason Lang, M.D., M.P.H.. The registered enrollment target is 41 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03015610, a Phase 3 study of Asthma and Gastroesophageal Reflux, has completed, sponsored by Jason Lang, M.D., M.P.H..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will evaluate the effect of CYP2C19 and ABCB1 genes on pharmacokinetics of lansoprazole in children with mild gastroesophageal reflux (GER) and uncontrolled asthma. It will determine if genotype-guided lansoprazole dosing of lansoprazole improves GER and asthma control.
Conditions Studied
Interventions
- DRUG commercially available lansoprazole
- DRUG matched placebo
Study Locations (2)
Florida
- Nemours Children's Specialty Care - Jacksonville
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2017-10-31 |
| Est. Completion | 2024-01-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03015610
The ClinicalTrials.gov registry entry for NCT03015610 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The listed sponsor is Jason Lang, M.D., M.P.H., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which commercially available lansoprazole is the first listed.
NCT03015610 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03015610 about?
NCT03015610 is a clinical study titled "Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma". This study will evaluate the effect of CYP2C19 and ABCB1 genes on pharmacokinetics of lansoprazole in children with mild gastroesophageal reflux (GER) and uncontrolled asthma. It will determine if genotype-guided lansoprazole dosing of lansoprazole improves GER and asthma control.
What is the current status of trial NCT03015610?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2017-10-31. Estimated completion is 2024-01-18.
What conditions does trial NCT03015610 study?
This clinical trial studies the following conditions: Asthma, Gastroesophageal Reflux.
What interventions are being tested in trial NCT03015610?
The interventions under investigation include: commercially available lansoprazole (DRUG), matched placebo (DRUG).
Who is sponsoring clinical trial NCT03015610?
This trial is sponsored by Jason Lang, M.D., M.P.H., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03015610 being conducted?
This trial has 2 study locations across Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
RECRUITING · Phase 3
-
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
RECRUITING · Phase 3
-
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
RECRUITING · Phase 3
-
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.